2014 European guideline on the management of syphilis

Janier, M.; Hegyi, Vladimír; Dupin, Nicolas; Unemo, Magnus; Tiplica, G.S.; Potočnik, Marko; French, Patrick; Patel, Reena

doi:10.5114/dr.2015.55318

Cited by 60 publications

(178 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Le diagnostic de Syphilis a été posé suite à cet échec de traitement. La syphilis est une infection sexuellement transmissible (IST) liée au Treponema Pallidum [2,3]. L'incidence de la maladie avait fortement diminué suite à au développement du traitement par pénicilline [3].…”

Section: Discussionunclassified

Diagnostic de syphilis et de VIH à partir d’ulcérations buccales

Campana¹,

Albertini²,

Ordioni³

2015

Med Buccale Chir Buccale

View full text Add to dashboard Cite

Section: Discussionunclassified

Diagnostic de syphilis et de VIH à partir d’ulcérations buccales

Campana¹,

Albertini²,

Ordioni³

2015

Med Buccale Chir Buccale

View full text Add to dashboard Cite

“…Tp invades the body mainly through the urogenital tract mucosa, while systemic humoral immunity and cellular immune response are key mechanisms to prevent Tp diffusion and to finally eradicate this bacterial infection (15,16). Specific SIgA antigen in the local mucosa serves an important role in the early resistance to Tp infection (17).…”

Section: Discussionmentioning

confidence: 99%

Intramuscular primary immunization by nucleic acid vaccine pcDNA/Gpd‑IL‑2 and enhanced immunization with mucosal adjuvant CpG‑ODN and Gpd‑IL‑2 recombinant protein effectively induced strong mucosal immune responses and immune protective effects against Treponema pallidum skin infection

et al. 2018

View full text Add to dashboard Cite

Abstract. The present study aimed to evaluate the immune effect of intramuscular primary immunization by the nucleic acid vaccine pcDNA/glycerophosphodiester phosphodiesterase-interleukin-2 (pcDNA/Gpd-IL-2) and enhanced immunization 2 weeks later with the combination of mucosal adjuvant CpG-oligodeoxynucleotides (ODN) and Gpd-IL-2 recombinant protein on skin infection caused by Treponema pallidum (Tp) in New Zealand rabbits. At week 8 following immunization, MTT assay was used to detect spleen cell proliferation, while enzyme-linked immunosorbent assay was performed to detect the cytokine and secretory immunoglobulin A (SIgA) levels. At week 10 after primary immunization, rabbits were inoculated with 10 5 Tp (Nichols strain). Alterations in the skin redness, swelling and ulceration were recorded for 0-60 days. In addition, positive rate of Tp in skin lesions and ulcer formation rate were examined using dark field and silver staining. The results indicated that intramuscular primary immunization by nucleic acid vaccine pcDNA/Gpd-IL-2 followed by enhanced immunization via nasal feeding with mucosal adjuvant CpG-ODN and Gpd-IL-2 recombinant protein induced the higher levels of Tp Gpd specific antibodies, increased the secretion of IL-2 and interferon-γ, and promoted the proliferation of T cells in the first 8 weeks after immunization. Furthermore, this immunization strategy stimulated the production of mucosa specific SIgA antibody. Thus, this strategy led to the lowest Tp positive and ulcer formation rates at the Tp infection sites, as well as healing of skin lesions on the earliest time point (day 42). In conclusion, immunization by nucleic acid vaccine pcDNA/Gpd-IL-2 followed by enhanced immunization with a combination of mucosal adjuvant CpG-ODN and Gpd-IL-2 recombinant protein is an effective immune strategy to induce strong mucosal immune responses and immune protective effects.

show abstract

“…The rest presented discordant results (23 positive with the rapid test and TPHA negative and 21 negative by rapid test and positive for TPHA). momento durante el embarazo y parto, siendo fundamental determinar su efectividad diagnóstica como alternativa valiosa en la implementación de programas de prevención y vigilancia del VIH y/o sífilis (1,2 (3)(4)(5).…”

Section: Introductionunclassified

“…Las pruebas serológicas se vuelven reactivas pasadas 3 a 4 semanas desde el inicio de las lesiones y la sensibilidad y especificidad de las mismas varían según los diferentes estadios de evolución de la enfermedad (1,3). La mayoría de estas pruebas necesitan de infraestructura de laboratorio no así la prueba rápida ya que se requiere un mínimo entrenamiento, y muy poca infraestructura.…”

Section: Introductionunclassified